Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Exclusion Criteria

• •Patients who have had surgery, chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have toxicity that has not recovered to =\< grade 1 from adverse events due to agents administered more than 4 weeks earlier (with the exception of alopecia); patients may not be receiving any other investigational agents
• •Histologic diagnosis of a benign or borderline tumor ('tumor of low malignant potential') or of a malignant tumor of non-epithelial origin (such as a germ cell tumor, sex-cord stromal tumor) of the ovary, fallopian tube or peritoneum
• •Patients with known brain metastases
• •History of allergic reactions to Cremophor EL, paclitaxel or its components
• •Prior history of \>= grade 2 neurotoxicity or any other toxicity requiring discontinuation of taxane therapy that has not resolved to =\< grade 1, with the exception of alopecia
• •Diagnosis of another malignancy within two years before the first dose, or previously treated for another malignancy with evidence of residual disease, with the exception of a synchronous endometrial cancer; carcinoma in situ will not be considered as malignancy
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, known serious cardiac illness or psychiatric illness/social situations that would limit compliance with study requirements; known serious cardiac illness or medical conditions include, but are not limited to:
• •* History of documented congestive heart failure (CHF), New York Heart Association (NYHA) class II/III/IV, with a history of dyspnea, orthopnea, or edema that requires current treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, beta blockers, or diuretics
• •* NOTE: use of these medications for the treatment of hypertension is allowed
• •* Screening QTc (QT interval corrected for heart rate) \> 470 msec or history of QT (cardiac interval from start of Q wave to end of T wave) prolongation while taking other medications
• •* High-risk uncontrolled arrhythmias (ventricular arrhythmias, high-grade atrioventricular \[AV\]-block, supra-ventricular arrhythmias that are not adequately rate-controlled)
• •* Arrhythmias that require current treatment with the following anti-arrhythmic drugs: flecainide, moricizine, or propafenone
• •* Current coronary artery disease with a history of myocardial infarction, angioplasty, or coronary bypass surgery within the preceding 6 months, or angina pectoris that has been symptomatic within the preceding 6 months
• •Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
• •Pregnant or breast feeding